Clinical trials: Cancer (With or Without Metastasis)
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Trial name
- NCT07673887
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 8 sites in United States, China and 2 more
- Volunteers
- 570 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Cancer, Estrogen Receptor-Positive Breast Cancer
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
- Trial name
- ENCORE301 (NCT00676663)
- Testing
- entinostat, exemestane
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 130 people
- Sponsor
- Syndax Pharmaceuticals
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with…
- Trial name
- NCT04716933
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 201 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer.
- Trial name
- MOUNTAINEER-03 (NCT05253651)
- Testing
- tucatinib, trastuzumab, bevacizumab
- Where
- 366 sites in United States, Argentina and 23 more
- Volunteers
- 400 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor
A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm
This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) ± CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male…
- Trial name
- AVENTURINE (NCT06940804)
- Testing
- CLDN6 CAR-T, CLDN6 RNA-LPX
- Sponsor
- BioNTech SE
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
This study is a Phase 1 and pharmacologic open-label dose-escalation trial using a "3+3" design. Successive cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified.
- Trial name
- NCT01304797
- Testing
- MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with trastuzumab q3w
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Merrimack Pharmaceuticals
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic…
- Trial name
- NCT03829319
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 158 sites in United States, Argentina and 15 more
- Volunteers
- 761 people
- Sponsor
- Merck Sharp & Dohme LLC
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small…
- Trial name
- NCT05949606
- Testing
- SI-B001, SI-B003
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
This randomized, open-label study will evaluate the safety and efficacy of Avastin (Bevacizumab) added to standard mFOLFOX6 chemotherapy in treatment-naïve patients with Stage IV metastatic colorectal cancer.
- Trial name
- NCT01338558
- Testing
- bevacizumab [Avastin], cetuximab, mFOLFOX6
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type…
- Trial name
- TAILOR (NCT01228734)
- Testing
- Cetuximab, Oxaliplatin, Folinic Acid
- Where
- 25 sites in China
- Volunteers
- 553 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer, Hormone Receptor Positive Tumor
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
This study is designed to evaluate the efficacy and safety of first-line treatment ribociclib in combination with aromatase inhibitor (AI) or fulvestrant OR capecitabine with bevacizumab OR paclitaxel with / without bevacizumab…
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
- Trial name
- RIBBIT (NCT03462251)
- Testing
- Ribociclib and aromatase inhibitor or fulvestrant, Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
- Where
- 27 sites in Germany
- Volunteers
- 41 people
- Sponsor
- iOMEDICO AG
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
- Trial name
- NCT02045602
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 5 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Theriva Biologics SL
Metastatic Pancreatic Cancer
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
- Trial name
- NCT03086369
- Testing
- Olaratumab, Nab-paclitaxel, Gemcitabine
- Where
- 34 sites in United States, Germany and 1 more
- Volunteers
- 184 people
- Sponsor
- Eli Lilly and Company
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor…
- Trial name
- monarcHER (NCT02675231)
- Testing
- Abemaciclib, Trastuzumab, Fulvestrant
- Where
- 93 sites in United States, Argentina and 12 more
- Volunteers
- 237 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung…
- Trial name
- LIBRETTO-431 (NCT04194944)
- Testing
- Selpercatinib, Carboplatin, Cisplatin
- Where
- 196 sites in Argentina, Australia and 24 more
- Volunteers
- 261 people
- Sponsor
- Eli Lilly and Company
Melanoma (Skin)
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells.Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00002767
- Testing
- Detox-B adjuvant, recombinant interferon alfa
- Where
- 27 sites in United States
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Metastatic Non-small Cell Lung Cancer
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to…
- Trial name
- NCT00806286
- Testing
- CS7017 tablets, Paclitaxel, Carboplatin
- Where
- 28 sites in United States, India and 2 more
- Volunteers
- 111 people
- Sponsor
- Daiichi Sankyo